People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

In October 2019, Janet Woodcock, then the director of the US Food and Drug Administration’s Center for Drug Evaluation and ...

On Thursday, the FDA approved Cobenfy, the first medication in decades to fight schizophrenia in a new way FRIDAY, Sept. 27, ...

We wouldn’t allow a new drug to be sold without thorough testing for safety and efficacy, so why should AI be any different?

For years, kratom has been clouded by controversy, largely fueled by media portrayals that paint a negative picture of this ...

Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral ...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

That’s where Novartis is expected to help. In addition to its expertise across drug discovery and development, the pharma giant has years of experience in AI, stretching back to 2019 when it ...

A Long Island man will spend 15 years behind bars for driving recklessly under the influence of drugs and causing a wrong-way collision that left a woman ...